000271077 001__ 271077
000271077 005__ 20250127091652.0
000271077 0247_ $$2pmid$$apmid:39053685
000271077 0247_ $$2doi$$a10.1016/j.brainres.2024.149128
000271077 0247_ $$2ISSN$$a0006-8993
000271077 0247_ $$2ISSN$$a1872-6240
000271077 037__ $$aDZNE-2024-00949
000271077 082__ $$a610
000271077 1001_ $$aStatz, Meike$$b0
000271077 245__ $$aSubthalamic nucleus deep brain stimulation induces functional deficits in norepinephrinergic neurotransmission in a Parkinson’s disease model
000271077 260__ $$aAmsterdam$$bElsevier$$c2024
000271077 3367_ $$2DRIVER$$aarticle
000271077 3367_ $$2DataCite$$aOutput Types/Journal article
000271077 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1723110613_2212
000271077 3367_ $$2BibTeX$$aARTICLE
000271077 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000271077 3367_ $$00$$2EndNote$$aJournal Article
000271077 520__ $$a Deep brain stimulation of the subthalamic nucleus (STN-DBS) is a successful treatment option in Parkinson's disease (PD) for different motor and non-motor symptoms, but has been linked to postoperative cognitive impairment.Since both dopaminergic and norepinephrinergic neurotransmissions play important roles in symptom development, we analysed STN-DBS effects on dopamine and norepinephrine availability in different brain regions and morphological alterations of catecholaminergic neurons in the 6-hydroxydopamine PD rat model.We applied one week of continuous unilateral STN-DBS or sham stimulation, respectively, in groups of healthy and 6-hydroxydopamine-lesioned rats to quantify dopamine and norepinephrine contents in the striatum, olfactory bulb and dentate gyrus. In addition, we analysed dopaminergic cell counts in the substantia nigra pars compacta and area tegmentalis ventralis and norepinephrinergic neurons in the locus coeruleus after one and six weeks of STN-DBS.In 6-hydroxydopamine-lesioned animals, one week of STN-DBS did not alter dopamine levels, while striatal norepinephrine levels were decreased. However, neither one nor six weeks of STN-DBS altered dopaminergic neuron numbers in the midbrain or norepinephrinergic neuron counts in the locus coeruleus. Dopaminergic fibre density in the dorsal and ventral striatum also remained unchanged after six weeks of STN-DBS. In healthy animals, one week of STN-DBS resulted in increased dopamine levels in the olfactory bulb and decreased contents in the dentate gyrus, but had no effects on norepinephrine availability.STN-DBS modulates striatal norepinephrinergic neurotransmission in a PD rat model. Additional behavioural studies are required to investigate the functional impact of this finding.
000271077 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000271077 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000271077 650_2 $$2MeSH$$aAnimals
000271077 650_2 $$2MeSH$$aSubthalamic Nucleus: metabolism
000271077 650_2 $$2MeSH$$aDeep Brain Stimulation: methods
000271077 650_2 $$2MeSH$$aMale
000271077 650_2 $$2MeSH$$aOxidopamine: toxicity
000271077 650_2 $$2MeSH$$aSynaptic Transmission: physiology
000271077 650_2 $$2MeSH$$aDopamine: metabolism
000271077 650_2 $$2MeSH$$aDisease Models, Animal
000271077 650_2 $$2MeSH$$aNorepinephrine: metabolism
000271077 650_2 $$2MeSH$$aRats
000271077 650_2 $$2MeSH$$aParkinson Disease: metabolism
000271077 650_2 $$2MeSH$$aParkinson Disease: therapy
000271077 650_2 $$2MeSH$$aDopaminergic Neurons: metabolism
000271077 650_2 $$2MeSH$$aOlfactory Bulb: metabolism
000271077 650_2 $$2MeSH$$aRats, Sprague-Dawley
000271077 650_2 $$2MeSH$$aCorpus Striatum: metabolism
000271077 650_2 $$2MeSH$$aDentate Gyrus: metabolism
000271077 650_2 $$2MeSH$$aParkinsonian Disorders: metabolism
000271077 650_2 $$2MeSH$$aParkinsonian Disorders: therapy
000271077 650_2 $$2MeSH$$aParkinsonian Disorders: physiopathology
000271077 7001_ $$aWeber, Hanna$$b1
000271077 7001_ $$aWeis, Frederike$$b2
000271077 7001_ $$aKober, Maria$$b3
000271077 7001_ $$aBathel, Henning$$b4
000271077 7001_ $$aPlocksties, Franz$$b5
000271077 7001_ $$avan Rienen, Ursula$$b6
000271077 7001_ $$aTimmermann, Dirk$$b7
000271077 7001_ $$0P:(DE-2719)9000306$$aStorch, Alexander$$b8$$udzne
000271077 7001_ $$aFauser, Mareike$$b9
000271077 773__ $$0PERI:(DE-600)1462674-3$$a10.1016/j.brainres.2024.149128$$gVol. 1841, p. 149128 -$$p149128$$tBrain research$$v1841$$x0006-8993$$y2024
000271077 8564_ $$uhttps://pub.dzne.de/record/271077/files/DZNE-2024-00949%20SUP.docx
000271077 8564_ $$uhttps://pub.dzne.de/record/271077/files/DZNE-2024-00949.pdf$$yOpenAccess
000271077 8564_ $$uhttps://pub.dzne.de/record/271077/files/DZNE-2024-00949%20SUP.doc
000271077 8564_ $$uhttps://pub.dzne.de/record/271077/files/DZNE-2024-00949%20SUP.odt
000271077 8564_ $$uhttps://pub.dzne.de/record/271077/files/DZNE-2024-00949%20SUP.pdf
000271077 8564_ $$uhttps://pub.dzne.de/record/271077/files/DZNE-2024-00949.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000271077 909CO $$ooai:pub.dzne.de:271077$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000271077 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000306$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000271077 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000271077 9141_ $$y2024
000271077 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN RES : 2022$$d2023-08-28
000271077 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000271077 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000271077 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-28
000271077 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-28$$wger
000271077 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-28
000271077 9201_ $$0I:(DE-2719)5000014$$kAG Storch$$lNon-Motor Symptoms in Parkinson's disease$$x0
000271077 980__ $$ajournal
000271077 980__ $$aVDB
000271077 980__ $$aUNRESTRICTED
000271077 980__ $$aI:(DE-2719)5000014
000271077 9801_ $$aFullTexts